8 results
Primary objective:To determine the safety and tolerability of multiple, once-daily oral doses of CNP520 over 13 weeks in healthy elderly subjectsSafety: ECG, vital signs and laboratory data; assessment of cognitive function; dermatological…
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1…
Our primary objective is to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra) improves beta-cell function in subjects with β-cell dysfunction.
The purpose of this study is to determine the effect of treatment on cognition, overall clinical status and underlying pathology in subjects with a risk of occurrence of the first clinical symptoms of Alzheimer's disease.People without…
PART I:Primary:• To investigate the safety and tolerability of two doses of VAD044 administered daily for up to 12 weeks in HHT patients.Secondary:• To assess the effects of two doses of VAD044 for up to 12 weeks of treatment on:o Epistaxis:•…
To investigate the effect on symptomatology of interference with IL-1 in CFS patients.
The aim of ImmunoSep is to study if personalized immunotherapy targeting either fulminant hyper-inflammation or immunoparalysis is able to improve sepsis outcomes.
The primary objective is to evaluate the efficacy of anakinra in patients with multiple myeloma receiving high-dose melphalan (HDM) in the preparation for an autologous hematopoietic stem cell transplantation (SCT). The primary endpoint is the…